Canadian CANNAINVESTOR Magazine August / September 2017 - Page 206

196

CANABO MEDICAL INC (TSXV:CMM; OTC:CAMDF)

Investing.com August 4 sentiment: STRONG BUY

According to their news releases, Canabo is the owner and operator of Canada's largest physician led referral-only cannabinoid clinics and with increasing referrals and resulting revenues combined with low market cap, there is little doubt as to why it is included in this case study. Recent highlights include:

- Their websites lists 17 locations across Canada and also a Patient Care call centre.

- Canabo announced it had entered into a collaborative agreement with Terra Life Sciences Inc to jointly work on the R&D and clinical application of cannabinoid-based treatments targeted to specific conditions.

- Secured additional clinics and access to over 15,000 additional patients. Canabo entered into a letter of intent with Aviva Medical Ltd. to enter into a share exchange agreement (“SEA”). Aviva Medical will operate five existing medical marijuana CMClinics in Ontario. Aviva Medical currently operates clinics in Hamilton, Stoney Creek, Burlington, and will assume operations of Canabo’s Barrie and St. Catharine’s clinics. It is proposed that Aviva Medical will open four new CMClinics Oakville, Niagara Falls, Peterborough and Etobicoke. Aviva Medical will operate a total of nine Canabo CMClinics in Ontario.

- In April, the company released its Milestone study that shows dramatic reduction in pharmaceutical reliance among Canadian medical cannabis patients.

DELIVRA CORP (TSXV:DVA)

Investing.com August 4 sentiment: NEUTRAL/BUY

Delivra entered the Cannabis and Hemp space approximately eight months ago with key partnerships. The company itself should be no stranger to Canadians because the #1 selling topical creams in Canada are from Delivra – the LivRelief and LivSport brand names. Normally, DVA would have been excluded from a case study given the current status of its industry presence; however, aggressive key partnerships, low market cap, relatively low number of issued and outstanding shares, strong and growing revenues (including international) warrant its inclusion and may be just the diversified company that some Retail Investors are looking for. Recent highlights include:

- Solidified the Company's position as having the #1 Selling Natural Pain Cream in Canada and the #1 Selling Nerve Pain Cream in Canada (adapted from Nielson data, April 2016). Its topical creams are also available for purchase in the USA.